Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 12/20 | 0.62 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.52 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.52 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.52 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.52 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.52 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19367186 | 1.00 | FKBP1A (0.62) | FKBP1AGABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL18510347 | 1.00 | FKBP1A (0.62) | FKBP1AGABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL19372465 | 0.86 | FKBP1A (0.66) | FKBP1A | |
| SCHEMBL5700640 | 0.82 | FKBP1A (0.67) | FKBP1A | |
| SCHEMBL5700650 | 0.82 | FKBP1A (0.66) | FKBP1A | |
| SCHEMBL7458418 | 0.81 | FKBP1A (0.60) | FKBP1A | |
| SCHEMBL18510345 | 0.80 | RIPK1 (0.65) | FKBP1A | |
| SCHEMBL14407876 | 0.79 | FKBP1A (0.52) | FKBP1A | |
| SCHEMBL6098874 | 0.78 | FKBP1A (0.71) | FKBP1A | |
| SCHEMBL6098871 | 0.78 | FKBP1A (0.71) | FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020191265-A1 | METHODS FOR TREATING PULMONARY FIBROSIS | DAVID WEINSTEIN CONSULTING, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| US-10709686-B2 | Methods for treating pulmonary fibrosis | DAVID WEINSTEIN CONSULTING, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190290612-A1 | METHODS FOR TREATING PULMONARY FIBROSIS | DAVID WEINSTEIN CONSULTING INC (US) | 2019-09-26 | — | — | US | disclosed |
| US-20180140576-A1 | METHODS FOR WOUND HEALING AND SCAR PREVENTION | DAVID WEINSTEIN CONSULTING INC (US) | 2018-05-24 | — | — | US | disclosed |
| US-20180140576-A1 | METHODS FOR WOUND HEALING AND SCAR PREVENTION | DAVID WEINSTEIN CONSULTING INC (US) | 2018-05-24 | — | — | US | disclosed |
| WO-2017165119-A1 | METHODS FOR WOUND HEALING AND SCAR PREVENTION | WEINSTEIN DAVID (US) | 2017-09-28 | — | — | WO | disclosed |
| US-20170266157-A1 | METHODS FOR WOUND HEALING AND SCAR PREVENTION | DAVID WEINSTEIN CONSULTING, INC. | 2017-09-21 | — | — | US | disclosed |
| US-20170266157-A1 | METHODS FOR WOUND HEALING AND SCAR PREVENTION | DAVID WEINSTEIN CONSULTING, INC. | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10709686-B2 | Methods for treating pulmonary fibrosis | FKBP4, FKBP1B, FKBP3 | FKBP1A 7/4885GABRA1 2619/4885GABRG2 2600/4885 |
| US-20180140576-A1 | METHODS FOR WOUND HEALING AND SCAR PREVENTION | FKBP4, S100A4, FKBP14 | FKBP1A 5/4885GABRA1 3278/4885GABRG2 3211/4885 |
| US-20170266157-A1 | METHODS FOR WOUND HEALING AND SCAR PREVENTION | FKBP4, S100A4, FKBP14 | FKBP1A 5/4885GABRA1 3278/4885GABRG2 3211/4885 |
| US-20190290612-A1 | METHODS FOR TREATING PULMONARY FIBROSIS | FKBP4, FKBP1B, FKBP3 | FKBP1A 7/4885GABRA1 2619/4885GABRG2 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.